Facing the treatment challenge of HER2-positive colorectal cancer, we fully understand your urgent desire for more effective and advanced treatment options. Today, we bring major encouraging news from China’s oncology field.
**Breakthrough Therapy Is Within Reach: SHR-A1811 Demonstrates Exceptional Potential**
On January 28, 2025, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration announced that SHR-A1811, an innovative antibody-drug conjugate (ADC) independently developed by Hengrui Pharma, is proposed for priority review. It is intended for the treatment of adult patients with HER2-positive colorectal cancer who have failed prior therapy with oxaliplatin, fluorouracil, and irinotecan. This marks a crucial step toward its clinical application in colorectal cancer, offering new hope for patients who have exhausted standard treatment options.
Having already demonstrated outstanding efficacy, this drug was approved in China in May 2025 for HER2-mutant non-small cell lung cancer, becoming China’s first independently developed ADC drug approved in that field. Now, its clinical data in colorectal cancer are equally promising: according to Phase 1 clinical trial results presented at the European Society for Medical Oncology (ESMO) Congress, at the recommended dose, the objective response rate (ORR) reached 46.9%, and the 6-month progression-free survival rate was as high as 85.5% in patients with HER2-positive colorectal cancer. These data indicate significant potential for survival improvement in patients with advanced HER2-positive colorectal cancer.
**Why Choose Beijing South Region Oncology Hospital International Department?**
Against the backdrop of rapidly advancing medical technology in China, how to access these cutting-edge treatments safely, promptly, and effectively is a core concern for international patients. Beijing South Region Oncology Hospital International Department was established precisely for this purpose:
1. **Fast Track to Advanced Therapies:** We closely monitor the latest drug approvals and clinical research developments in China. We can assess and provide eligible international patients with access to advanced treatment options.
2. **International-Standard Comprehensive Services:** From professional medical consultation and bilingual (Chinese-English) translation & evaluation of medical records to precise visa invitation letter processing, followed by “one-stop” considerate accompaniment during hospitalization, daily life assistance, and post-discharge follow-up, we offer comprehensive, personalized services to ensure a smooth and worry-free medical journey in China.
3. **Top-Tier Medical Team and Environment:** The hospital brings together renowned oncology experts from across China, equipped with advanced diagnostic and therapeutic technology. We also provide comfortable international patient wards and a patient-centered treatment environment, ensuring care is delivered with both scientific excellence and compassion.
**Contact Us Now to Begin Your Journey of Hope**
We understand the critical importance of time in cancer treatment. If you or your loved one is facing HER2-positive colorectal cancer or other oncological challenges and wishes to learn more about SHR-A1811 or other latest treatment options, please do not hesitate to contact us immediately through any of the following channels:
- Service Hotline: 400-880-3716
**Other Convenient Contact Methods:**
- **WeChat:** Please add ID `17801183037`. Our medical coordinators will provide instant online communication assistance.
- **Email:**
- 100085_010@163.com
- myimmnet@163.com
You may send your medical summary and relevant test reports to the above email addresses, and we will arrange for a preliminary expert evaluation.
Every technological breakthrough carries new hope for countless lives. Beijing South Region Oncology Hospital International Department is committed to being your trusted partner in the fight against disease, offering professional medical expertise and warm international services.
**Beijing South Region Oncology Hospital International Department: In Step with the World, Safeguarding Life.**
Post time: Jan-29-2026